Cardiol Therapeutics Secures $11M Financing
Ticker: CRDL · Form: 6-K · Filed: Oct 17, 2025 · CIK: 1702123
Sentiment: bullish
Topics: financing, biotech, funding
TL;DR
Cardiol Therapeutics just raised $11M, pushing their cash runway to Q3 2027. Big win for R&D.
AI Summary
Cardiol Therapeutics Inc. announced on October 17, 2025, that it has secured US$11 million in financing. This funding is expected to extend the company's cash runway into the third quarter of 2027, providing crucial capital for its operations and development.
Why It Matters
This financing provides Cardiol Therapeutics with significant capital to continue its research and development efforts, potentially advancing its drug candidates and extending its operational runway.
Risk Assessment
Risk Level: medium — While the financing is positive, the company operates in the highly speculative biotechnology sector, and the success of its drug development pipeline remains uncertain.
Key Numbers
- US$11 million — Financing Secured (This capital infusion is critical for funding ongoing research and development activities.)
- Q3 2027 — Extended Cash Runway (Indicates the company has sufficient funds to operate for an extended period, reducing immediate financial pressure.)
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — The company filing the report and announcing the financing.
- US$11 million (dollar_amount) — The amount of financing secured by the company.
- Q3 2027 (date) — The extended cash runway provided by the financing.
- October 17, 2025 (date) — The date of the news release announcing the financing.
FAQ
What is the primary purpose of the US$11 million financing?
The financing is intended to extend Cardiol Therapeutics' cash runway into Q3 2027, providing capital for its operations and development.
When was the financing announced?
The financing was announced in a news release dated October 17, 2025.
What is the expected impact of this financing on Cardiol Therapeutics' operations?
The financing is expected to provide Cardiol Therapeutics with sufficient capital to continue its operations and development activities until Q3 2027.
What is Cardiol Therapeutics Inc.'s principal executive office address?
Cardiol Therapeutics Inc.'s principal executive office is located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
What type of filing is this Form 6-K report?
This is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
Filing Stats: 174 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2025-10-17 17:17:11
Key Financial Figures
- $11 Million — , 2025 - Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into
Filing Documents
- form6k.htm (6-K) — 5KB
- exhibit99-1.htm (EX-99.1) — 13KB
- exhibit99-1xu002.jpg (GRAPHIC) — 7KB
- 0001062993-25-016192.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: October 17, 2025 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer